Skip to main contentSkip to navigation
Sirius Investors

BVNRY Stock: Bavarian Nordic A/S Stock Price, Analysis & Insights

Get live BVNRY stock price $9.38, comprehensive Bavarian Nordic A/S stock analysis, charts, news, and expert forecast. Real-time BVNRY stock data and investment insights.

9.38
0.81%Today
BVNRYBavarian Nordic A/S • Other OTC • Healthcare
Market Cap
2.17B
Volume
283
52W High
13.00
52W Low
8.66

Loading chart data...

Bavarian Nordic A/S (BVNRY) Overview

Bavarian Nordic A/S (BVNRY) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, BVNRY trades at $9.38 with a market capitalization of 2.17B . Over the past 52 weeks, BVNRY has traded between $8.66 and $13.00 , with the current price positioned at approximately 16% of this range . The stock currently trades at...

Key Takeaways

  • Operates in the Healthcare sector (Biotechnology)
  • Market cap: 2.17B
  • Current price: $9.38
  • 52-week range: $8.66 - $13.00
  • P/E ratio: 12.02

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypo...

Company Information

CEO
Paul John Chaplin
Sector
Healthcare
Industry
Biotechnology
Employees
1645

Contact Information

Address
Philip Heymans Alle 3
Country
DK

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Valuation metrics suggest potential value opportunity (P/E: 12.0)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Bavarian Nordic A/S shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Bavarian Nordic A/S
  • Investors should consider how Bavarian Nordic A/S fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

2.17B

P/E Ratio (TTM)

12.02

Beta

0.96

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.